SynGenSys
PrivateLast Round
Seed
Apr 1, 2025
Total Funding Raised
$4.09M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SynGenSys operates in Healthcare & Life Sciences and is based in Sheffield. Its latest recorded funding round was a Seed round in April 2025.
SynGenSys is a biotechnology company that designs synthetic gene promoter systems to address bottlenecks in biopharma manufacturing and enhance cell and gene therapy development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynGenSys Comparables
Compare SynGenSys with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chromatin Bioscience | 92% | |
| Concinnity Genetics | 82% | |
| Annogen | 81% |
For institutional investors. Book with your work email.
SynGenSys Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Apr 1, 2025 | ||||
| Seed | Apr 3, 2024 |
For institutional investors. Book with your work email.
SynGenSys Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UKRI Innovate UK | Seed |
| Takeda Ventures | Seed |
| The University of Sheffield | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 106% MoM, reaching 3.1K.
- Jul 20, 2026
Open roles increased to 5, 2.1x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 18, 2026
Syngensys Ltd appoints Dr Thilo Pohle as Head of Commercial in United Kingdom on Jul 22nd '26, giving him responsibility for commercialising and driving industry adoption of its synthetic promoter and signal peptide technologies.
- hiresSep 18, 2026
Syngensys Ltd appoints Dr Abayomi Johnson as Head of Cell and Gene Therapy Expression Technologies, where he oversees the development of expression technologies for cell and gene therapy applications.
- launchesAug 13, 2026
Syngensys Ltd introduces CHO.SET 2.0, an expanded synthetic promoter library that enables tunable transgene expression and increased CHO cell productivity, in United Kingdom on Aug 20th '26.
For institutional investors. Book with your work email.
SynGenSys Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SynGenSys's valuation, stock price, and market status.
Is SynGenSys a public or private company?
SynGenSys is a private company.
What is the current stock price of SynGenSys?
SynGenSys is a private company, so its shares have no public market price. Caplight tracks SynGenSys's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynGenSys worth (valuation)?
Valuation information for SynGenSys is not publicly available.
Can I buy SynGenSys stock?
SynGenSys shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynGenSys's last funding round?
SynGenSys's most recent funding round was Seed on April 1, 2025.
Who are the main investors in SynGenSys?
Key investors in SynGenSys include UKRI Innovate UK, Takeda Ventures, The University of Sheffield.
Will SynGenSys IPO soon?
No public IPO plans have been announced for SynGenSys.
How can I track SynGenSys secondary market activity?
Caplight tracks bids, offers, and trades in SynGenSys's shares on secondary markets.